Findings

What do systematic reviews say?

4,751 questions · 12,775 findings · 807 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,413 · 26.7%GRADE not reported 709 · 5.5%Very low 3,483 · 27.3%Low 3,165 · 24.8%Moderate 1,628 · 12.7%High 377 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Mycophenolate mofetil vs cyclophosphamide

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mycophenolate mofetil vs cyclophosphamide

Dialysis · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1 [0.14, 6.9]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Relapse · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.8 [1, 3.22]
1 study · 127 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Remission · adults with renal vasculitis

Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [1.01, 1.35]
3 studies · 216 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Infection · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.27 [0.75, 2.16]
3 studies · 216 participants
Moderate

IVIg vs placebo

Death · adults with renal vasculitis

Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.88]
1 study · 34 participants
Low

Intervention not reported

Dialysis at one year · adults with renal vasculitis

The intervention may leads to lower dialysis at one year (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.45 [0.29, 0.72]
6 studies · 235 participants
Low

IVIg vs placebo

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Dialysis · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Response at 3 months · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 2.33 [1.18, 4.61]
1 study · 34 participants
Low

IVIg vs placebo

Relapse at 3 months · adults with renal vasculitis

Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [0.39, 3.56]
1 study · 34 participants
Low

IVIg vs placebo

Adverse events · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 3
1 study · 34 participants
Low

IVIg vs placebo

Serious infection · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine vs cyclophosphamide

Death (all causes) · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.77 [0.35, 1.72]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Kidney function · adults with renal vasculitis for maintenance therapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine vs cyclophosphamide

Dialysis · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in dialysis (median compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.65 [0.57, 4.79]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Relapse · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in relapse at 18 months compared with cyclophosphamide (moderate certainty).

2 findings from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.13 [0.51, 2.5]
1 study · 144 participants
Moderate
Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.46 [1, 2.14]
1 study · 144 participants
Moderate

Intervention not reported

Sustained remission · adults with renal vasculitis

The intervention may leads to higher sustained remission (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.02
1 study · 704 participants
Low

Azathioprine vs cyclophosphamide

Serious adverse events · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.18 [0.45, 3.07]
1 study · 144 participants
Moderate